دورية أكاديمية
Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
| العنوان: | Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. |
|---|---|
| المؤلفون: | Wu HX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Pan YQ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., He Y; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Wang ZX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Guan WL; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Chen YX; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Yao YC; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Shao NY; Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau, China.; MoE Frontiers Science Center for Precision Oncology, University of Macau, Taipa, Macau, China., Xu RH; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Wang F; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. |
| المصدر: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 20; Vol. 41 (9), pp. 1735-1746. Date of Electronic Publication: 2022 Dec 06. |
| نوع المنشور: | Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology Original Publication: New York, N.Y. : Grune & Stratton, c1983- |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy , Esophageal Squamous Cell Carcinoma*/drug therapy , Esophageal Neoplasms*/drug therapy, Humans ; B7-H1 Antigen/metabolism ; Programmed Cell Death 1 Receptor ; Ligands ; Apoptosis ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use |
| مستخلص: | Purpose: Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food and Drug Administration approved this regimen regardless of PD-L1 expression. The superiority of programmed death-1 (PD-1) antibody plus chemotherapy over chemotherapy alone in patients with low PD-L1-expressing ESCC remains debatable. Methods: Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to identify eligible randomized controlled trials for meta-analysis. Study-level pooled analyses of hazard ratios (HRs) for overall survival and progression-free survival and odds ratios for objective response rate according to PD-L1 expression were performed. Results: The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five randomized controlled trials were included in the meta-analysis, and two PD-L1 expression scoring criteria, TPS (≥ 1%/< 1%) and combined positive score (CPS, ≥ 10/< 10), were analyzed. Significant overall survival benefit by adding PD-1 antibody to chemotherapy was observed in both the TPS < 1% (HR, 0.74; 95% CI, 0.56 to 0.97) and CPS < 10 (HR, 0.77; 95% CI, 0.66 to 0.89) subgroups. Similarly, significantly prolonged progression-free survival was observed in both the TPS < 1% (HR, 0.66; 95% CI, 0.50 to 0.86) and CPS < 10 (HR, 0.63; 95% CI, 0.47 to 0.84) subgroups. In addition, the objective response rate of the TPS < 1% subgroup was significantly improved (odds ratio, 1.71; 95% CI, 1.27 to 2.29). In all high PD-L1-expressing subgroups, the pooled benefit of PD-1 antibody plus chemotherapy was significantly better than that of chemotherapy. Conclusion: This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of predictive biomarkers are warranted. |
| التعليقات: | Comment in: J Clin Oncol. 2023 May 20;41(15):2862-2864. (PMID: 36977308) |
| References: | Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. (PMID: 33580222) N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635) J Clin Oncol. 2020 Dec 10;38(35):4138-4148. (PMID: 33026938) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Lancet. 2021 Aug 28;398(10302):759-771. (PMID: 34454674) JAMA Netw Open. 2020 Oct 1;3(10):e2013770. (PMID: 33017026) N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174) Clin Cancer Res. 2022 Feb 1;28(3):489-497. (PMID: 34740921) Lancet. 2013 Feb 2;381(9864):400-12. (PMID: 23374478) J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. (PMID: 31319389) J Thorac Oncol. 2018 Sep;13(9):1302-1311. (PMID: 29800747) JAMA. 2021 Sep 14;326(10):916-925. (PMID: 34519801) J Clin Oncol. 2022 Sep 10;40(26):3065-3076. (PMID: 35442766) N Engl J Med. 2017 Jun 22;376(25):2415-2426. (PMID: 28636851) Lancet Oncol. 2020 Jun;21(6):832-842. (PMID: 32416073) Clin Cancer Res. 2018 Mar 15;24(6):1296-1304. (PMID: 29358502) Lancet. 2017 Nov 25;390(10110):2383-2396. (PMID: 28648400) BMJ. 2022 Apr 19;377:e068714. (PMID: 35440464) Nat Commun. 2017 Nov 16;8(1):1533. (PMID: 29142225) JAMA Oncol. 2019 Apr 01;5(4):546-550. (PMID: 30570649) J Thorac Oncol. 2017 Feb;12(2):208-222. (PMID: 27913228) Lancet. 2021 Mar 13;397(10278):1010-1022. (PMID: 33285141) N Engl J Med. 2022 Feb 3;386(5):449-462. (PMID: 35108470) Lancet Oncol. 2019 Nov;20(11):1506-1517. (PMID: 31582355) Cancer Cell. 2022 Mar 14;40(3):277-288.e3. (PMID: 35245446) Nat Commun. 2022 Feb 14;13(1):857. (PMID: 35165274) N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) Ann Oncol. 2019 Sep 1;30(9):1479-1486. (PMID: 31236579) N Engl J Med. 2014 Dec 25;371(26):2499-509. (PMID: 25539106) |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 0 (Programmed Cell Death 1 Receptor) 0 (Ligands) |
| تواريخ الأحداث: | Date Created: 20221206 Date Completed: 20230320 Latest Revision: 20230528 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10022847 |
| DOI: | 10.1200/JCO.22.01490 |
| PMID: | 36473145 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1527-7755 |
|---|---|
| DOI: | 10.1200/JCO.22.01490 |